FDA Clears Biora's IND Application For BT-600 In Ulcerative Colitis Treatment; Stock Surges

(RTTNews) - Biora Therapeutics Inc. (BIOR) said that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis. https://www.nasdaq.com/articles/fda-clears-bioras-ind-application-for-bt-600-in-ulcerative-colitis-treatment-stock-surges